Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Pfizer
M.D. Anderson Cancer Center
Erasca, Inc.
Sichuan Enray Pharmaceutical Sciences Company
AstraZeneca
Arvinas Inc.
University of Colorado, Denver
Alliance for Clinical Trials in Oncology
Pfizer
xCures
University of Nebraska
Zhejiang University
Adela, Inc
Eli Lilly and Company
Bayer
Eli Lilly and Company
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Ikena Oncology
Eli Lilly and Company
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
Azienda Ospedaliera di Padova
Turning Point Therapeutics, Inc.
Apollomics Inc.
ModeX Therapeutics, An OPKO Health Company
TransThera Sciences (Nanjing), Inc.
Hoffmann-La Roche
Instituto do Cancer do Estado de São Paulo
Columbia University
Nanjing First Hospital, Nanjing Medical University
Eli Lilly and Company
Theratechnologies
Xynomic Pharmaceuticals, Inc.
Cedars-Sinai Medical Center
Rutgers, The State University of New Jersey
Sotio Biotech Inc.
VitaMed Research LLC
Salubris Biotherapeutics Inc
NantCell, Inc.
Turning Point Therapeutics, Inc.
ABM Therapeutics Corporation
TransThera Sciences (Nanjing), Inc.
Beijing Friendship Hospital
Istituti Clinici Scientifici Maugeri SpA
Eli Lilly and Company
M.D. Anderson Cancer Center
Kineta Inc.